All News

Eisai has applied to voluntarily withdraw lorcaserin hydrochloride (Belviq) in both its original and extended release forms.

Results from a new retrospective analysis have shown that patients prescribed tiotropium bromide (Spiriva Respimat) inhalation spray 1.25 mcg experienced fewer asthma-related exacerbations when the treatment was added to a combination inhaled corticosteroid and long-acting beta2 agonist (ICS + LABA), compared with patients who received an increased dose of ICS + LABA.

The scope of HIV/AIDS treatment in America has changed immensely in recent years across the pharmacy landscape. Roosevelt University's College of Pharmacy (RUCOP) is helping to highlight this shift in its updated HIV/AIDS care and training program.

Although the number of US cases is still low, experts are raising concerns that the US reliance on China for pharmaceutical ingredients could result in drug shortages as Chinese officials battle the outbreak.

A new economic analysis published in JAMA found that the implementation of reference pricing increased the percentage of prescriptions filled for the lower-priced drugs within each therapeutic class, while simultaneously increasing patient cost sharing and decreasing overall prices paid.

The DKFZ discovered traces of a total of 23 different virus types in 356 patients with cancer. The most common drivers of tumor initiation and growth were found, including the genome of Epstein-Barr viruses (EBV) and hepatitis B virus (HBV).

WHO Strategy Could End Cervical Cancer Tops SPT Week in Review

Top news from across the health care landscape.

Listerine, the product named after pharmacist Joseph Lister, had many original uses before becoming a mouthwash. What was one of the original ways that Listerine was sold as?

Coughing is highly prevalent in all medical settings and affects a wide variety of body systems.

Physicians treating patients with platinum-sensitive ovarian cancer can choose from a range of therapies, including doublet chemotherapy with or without bevacizumab (Avastin) and PARP inhibitors.

Researchers from George Washington University have shown that the human apolipoprotein A-I binding protein (AIBP) is capable of inhibiting HIV replication by targeting lipid rafts and reducing virus-cell fusion.

There are 5 available EGFR TKIs for the treatment of patients with EGFR-mutant lung cancers: gefitinib (Iressa), erlotinib (Tarceva), afatinib (Gilotrif), dacomitinib (Vizimpro), and osimertinib.

Adam Martin, PharmD and founder of The Fit Pharmacist, discusses how to change your mindset about nutrition and health.

The Fair Access to Cancer Treatment Act is expected to be signed by Governor Tom Wolf in the near future.

Top news from across the health care landscape.

Study findings provide further basis for dietary interventions as future treatments for disorders such as multiple sclerosis.

CAR NK cells are allogenic, which is defined as taking the cells from a non-related healthy donor rather than the patient themselves. Therefore, CAR NK cells have the potential to be manufactured in advance and stored for off-the-shelf immediate use.

Top news from across the health care landscape.

This week’s tip examines a comprehensive set of pharmacist-based interventions in acute care settings.

Based on molecular similarities in human and canine diffuse gliomas, researchers have posited that working to cure brain cancer in dogs may lead to improved treatments and even a cure for humans.

Dronabinol Capsules is the generic version of Marinol® from Abbvie and is used to nausea and vomiting caused by cancer chemotherapy.

Community pharmacy antibiotic dispensing data were obtained from the New Zealand Pharmaceutical Collection database for children whose parents consented to external data linkage.

Decreased PrEP usage was reportedly due to reduced awareness of prevention strategies, and engagement in health-promoting behaviors.

Several immunization recommendations were updated for pediatric patients, including haemophilus influenza type b (Hib) vaccination, and Tdap vaccinations.

Positive results were based on the PROSPER trial, which evaluated the overall survival of enzalutamide plus androgen deprivation therapy versus standard of care.

Capmatinib is an investigational, oral, and selective MET inhibitor, and if approved, it will be the first therapy to specifically target METex14 mutated advanced lung cancer, according to the company.

While KTE-X19 is not yet approved in any country, its Marketing Authorization Application has been validated in the European Union, and its target action date in the United States is August 10, 2020.